Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Esperion ( (ESPR) ) is now available.
On October 7, 2025, Esperion Therapeutics announced an underwritten public offering of 30,000,000 shares of its common stock at $2.50 per share, with an option for underwriters to purchase an additional 4,500,000 shares. The offering is expected to close around October 9, 2025, and aims to raise approximately $70.2 million, or $80.7 million if the option is fully exercised. The proceeds will primarily fund the commercialization of NEXLETOL and NEXLIZET, research and development, and general corporate purposes. This move is part of Esperion’s strategy to strengthen its financial position and support its ongoing operations and growth initiatives.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Spark’s Take on ESPR Stock
According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.
Esperion’s overall stock score is driven by strong technical momentum and positive earnings call highlights. However, financial performance and valuation challenges, including negative equity and ongoing losses, weigh heavily on the score. Corporate events provide some positive sentiment, but the financial instability remains a significant concern.
To see Spark’s full report on ESPR stock, click here.
More about Esperion
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The company has developed the only FDA-approved oral, once-daily, non-statin medicines for patients at risk for cardiovascular disease. Esperion is also advancing its pre-clinical pipeline with a focus on ATP citrate lyase inhibitors (ACLYi).
Average Trading Volume: 6,223,378
Technical Sentiment Signal: Buy
Current Market Cap: $629.1M
See more insights into ESPR stock on TipRanks’ Stock Analysis page.